NCCN Research & Business Resources
Find a clinical trial >
The mission of the Fred & Pamela Buffett Cancer Center is to coordinate cancer care, research and education in Nebraska, the region and the world.
Respected for decades as the Eppley Cancer Center, the new name, Fred & Pamela Buffett Cancer Center, and its future home, create greater possibilities for cancer research and care.
Currently under construction, the new Fred & Pamela Buffett Cancer Center facility is scheduled to open in 2017. Health care providers and researchers will work side-by-side in state-of-the-art, integrated facilities to speed up breakthroughs in the lab and ensure personalized patient care. The largest project ever on campus, the $323 million facility will include a 252,000 square foot cancer research tower and 323,000 square foot clinical treatment facility which includes ambulatory and inpatient services.
As the only National Cancer Institute-designated cancer center in Nebraska, the Fred & Pamela Buffett Cancer Center provides the best in science and clinical practice. Today, more than 200 oncologists and basic scientists are working together to find better ways to diagnose, treat and prevent cancer.
For over 50 years, our scientists and physicians have been at the forefront of discoveries that have increased survivorship. We’ve treated people from all 50 states and more than 42 different countries. Our strengths in lymphoma, leukemia, breast cancer, pancreatic and gastrointestinal cancers, head and neck cancers, brain cancer, lung cancer, pediatric oncology and research have meant unmatched care for Nebraska, the region and the world.
ACCREDITATION & AWARDS
- U.S. News & World Report
- National Comprehensive Cancer Network
- The National Comprehensive Cancer Network (NCCN) is an alliance of the world’s leading cancer centers, working together to develop national treatment guidelines for cancers based on the latest research. The Fred & Pamela Buffett Cancer Center is one of the founding members.
- National Cancer Institute (NCI) Designation
- This designation recognizes the Fred & Pamela Buffett Cancer Center offers patients options for prevention, diagnosis and treatment and access to clinical trials not available elsewhere.
- American College of Radiology
- The American College of Radiology (ACR) recognizes the highest standards for quality practice in clinical imaging, personnel expertise and an ongoing commitment to quality improvement.
- American College of Surgeons Commission on Cancer
- This accreditation ensures patients receive comprehensive, state-of-the-art services provided by a multi-specialty team coordinating all aspects of cancer care.
- Foundation for the Accreditation of Cellular Therapy (FACT)
- The FACT accreditation demonstrates our commitment to quality in cellular therapy and blood and marrow transplantation and ensures our transplant program meets rigorous international standards.
- Magnet Status
- Magnet Status is awarded by the American Nurses Credentialing Center (ANCC) and is the highest level of recognition for excellence in nursing practice.
- Oncology Certified Nurses
- Oncology Certified Nurses (OCN) working at Nebraska Medicine obtain certification in Oncology Nursing.
- Blue Distinction Center
- First hospital in the state to receive the Blue Cross and Blue Shield of Nebraska, Blue Distinction Center for Complex and Rare Cancers. Only 88 other medical centers in the United States have earned the same distinction. Blue Distinction Centers for Complex and Rare Cancers were developed in strategic collaboration with the National Comprehensive Cancer Network (NCCN) and input from a panel of leading clinicians and professional organizations.
- Best Doctors of America
- 176 physicians at Nebraska Medicine are recognized among the “Best Doctors of America”
Considered to be a Center of Excellence for the study of lymphoma, much emphasis is placed on integrated laboratory and clinical research in this disease. The Center's Lymphoma Study Group has reviewed more than 40,000 biopsies and created a clinical outcome database to correlate the findings. Nebraska Medicine’s stem cell transplantation program has been ranked as one of the busiest adult and pediatric stem cell transplantation programs in the world. The program, which was established in 1983, has been recognized internationally for pioneering autologous transplantation for lymphoma, using peripheral stem cells as an alternative rescue product; conducting ground-breaking transplant studies; and performing transplants in alternate settings other than traditional inpatient hospital units.
The Fred & Pamela Buffett Cancer Center has a $5.3 million National Cancer Institute Specialized Program of Research Excellence (SPORE) grant in pancreatic cancer. SPORE offers large, multidisciplinary federal grants that fund scientific research aimed at bringing new laboratory findings quickly to the clinic.
Nationally recognized breast cancer researchers along with a strong nucleus of established breast cancer researchers at UNMC, enable the Cancer Center to create a Center for Breast Cancer Research that will transform the breast cancer research program at the Fred & Pamela Buffett Cancer Center into a world-class research program for breast cancer detection, prevention, and treatment.
Stem Cell Transplant Program:
The diseases most treated using stem cell transplantation are non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, multiple myeloma and solid tumors (including breast cancer or testicular cancer). Various other hematological and non-hematological diseases are treated on a case by case basis. Autologous, related and unrelated myeloablative allogeneic, related and unrelated non-myeloablative, and cord blood transplants are provided for adults and children. The program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT).
The Fred & Pamela Buffett Cancer Center offers radiation therapy as a highly effective and targeted cancer therapy used in 70 percent of all cancer patients. Revolutionary advances in Radiation Oncology have been made over the past 10-15 years. More precise and targeted therapy delivery and improvements in imaging help physicians spare normal tissues to a greater degree than in past years. Radiation therapy is often used in conjunction with other treatment modalities, such as surgery or chemotherapy, or can be used as the sole treatment modality.
The Fred & Pamela Buffett Cancer Center has a robust surgical oncology program offering patients unique treatment options not available elsewhere. The program offers a comprehensive approach to cancer care with the largest number of fellowship-trained surgical oncologists in the Midwest. Several areas of surgical therapies are available at the Fred & Pamela Buffett Cancer Center including gastrointestinal, orthopaedic, urologic, thoracic, gynecologic, head and neck, plastic and reconstructive and neuro-oncology.
EXCELLENCE IN RESEARCH
Research efforts are organized into four main research programs which facilitate collaboration between basic science and clinical researchers through participation in program activities and focus group meetings. The Fred & Pamela Buffett Cancer Center research programs include:
- Cancer Genes and Molecular Regulation Program (CGMRP)
- Members in this program study the mechanisms that cause cells to become malignant and form tumors.
- Molecular Biochemical Etiology Program (MBEP)
- Researchers in this program stimulate collaborative multidisciplinary research to further our understanding of the molecular and biochemical events leading to oncogenesis and to develop strategies for abrogating these events.
- Lymphoma Research Program (LRP)
- Research in this program is focused on identifying causes, evaluation of molecular markers of prognosis, and development of new therapies for lymphomas.
- Cancer Prevention and Control Program (CPCP)
- Members in this developing program focus on improving the current knowledge base for promoting overall reductions in cancer incidence, morbidity, and mortality, as well as conducting research on reducing cancer risk and incidence, reducing complications secondary to cancer, managing symptoms and improving quality of life and survivorship.